Tsang R W, Brierley J D, Panzarella T, Gospodarowicz M K, Sutcliffe S B, Simpson W J
Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.
Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):557-65. doi: 10.1016/0360-3016(92)90941-a.
Radiation therapy is often an integral part of postoperative treatment in patients with nonfunctional pituitary adenomas. The Princess Margaret Hospital (PMH) experience was reviewed and analyzed to establish the role of radiation therapy in local control relative to its complications, and to see if subgroups of patients with a greater or lesser risk of recurrence postsurgery can be defined.
Records of 160 patients with nonfunctional pituitary adenoma treated between 1972 and 1986 were reviewed retrospectively. The review focused on 128 patients treated with surgery and postoperative radiation as initial therapy. The median total dose was 45 Gy. Local tumor control was defined as lack of progression or recurrence of adenoma as assessed clinically and by imaging studies. The following factors were analyzed for prognostic significance in local tumor control: age, sex, direction of tumor extension, radiation dose, and preoperative tumor size as reflected by the radiation field size. Complications including hypopituitarism and second tumors were analyzed. Hypopituitarism was defined as requirement for permanent hormone replacement therapy.
With a median follow-up duration of 8.3 years, the 10-year actuarial local control rate was 87% for the entire 160 patients and 91% for the 128 patients given postoperative radiation as initial treatment. For the 29 patients referred for treatment of recurrent tumor, the 10-year local control rate was 78%. Prognostic factors for local control identified in univariate analysis included age (p = 0.005) and radiation field size (p = 0.0001). Older patients and those with larger tumors requiring large radiation portals were less likely to achieve durable local control. These two factors remained significant in a multivariate analysis (p < 0.005). The major complication, hypopituitarism requiring hormonal replacement with thyroxine, glucocorticoid, and sex hormone was observed to date in 65% (100 out of 155), 68% (105 out of 154), and 67% (85 out of 127) of evaluable patients, respectively. Radiation was the contributing cause of the hypopituitarism in only 23%, 16%, and 13%, respectively. There were no cases of brain necrosis or radiation damage to the optic pathways. Two patients developed a fatal in-field glioma of the brain stem at 10 and 15 years following radiation.
Postoperative external beam radiation therapy is highly effective in preventing recurrence of hormonally inactive pituitary adenomas. Hypopituitarism is commonly observed, but radiation can only be incriminated as the contributing cause in approximately one-fifth of the cases. Treatment of patients at the time of recurrence gave comparable local control rates to those irradiated initially. Favorable patients (age < or = 50, with small tumors removed totally) probably can be safely observed postoperatively with radiation reserved for recurrence.
放射治疗通常是非功能性垂体腺瘤患者术后治疗的重要组成部分。回顾并分析了玛格丽特公主医院(PMH)的经验,以确定放射治疗在局部控制方面相对于其并发症的作用,并探讨是否可以定义术后复发风险较高或较低的患者亚组。
回顾性分析了1972年至1986年间治疗的160例非功能性垂体腺瘤患者的记录。重点研究了128例接受手术和术后放疗作为初始治疗的患者。中位总剂量为45 Gy。局部肿瘤控制定义为根据临床评估和影像学研究,腺瘤无进展或复发。分析了以下因素对局部肿瘤控制的预后意义:年龄、性别、肿瘤扩展方向、放射剂量以及由放射野大小反映的术前肿瘤大小。分析了包括垂体功能减退和二次肿瘤在内的并发症。垂体功能减退定义为需要永久性激素替代治疗。
中位随访时间为8.3年,160例患者的10年精算局部控制率为87%,128例接受术后放疗作为初始治疗的患者为91%。对于29例转诊治疗复发性肿瘤的患者,10年局部控制率为78%。单因素分析确定的局部控制预后因素包括年龄(p = 0.005)和放射野大小(p = 0.0001)。老年患者和肿瘤较大需要大放射野的患者不太可能实现持久的局部控制。在多因素分析中,这两个因素仍然具有显著性(p < 0.005)。主要并发症,即需要用甲状腺素、糖皮质激素和性激素进行激素替代的垂体功能减退,在可评估患者中分别有65%(155例中的100例)、68%(154例中的105例)和67%(127例中的85例)出现。放射仅分别在23%、16%和13%的病例中是垂体功能减退的促成原因。没有脑坏死或视路放射损伤的病例。两名患者在放疗后10年和15年发生了致命的脑干野内胶质瘤。
术后外照射放疗在预防无功能性垂体腺瘤复发方面非常有效。垂体功能减退很常见,但放射仅在约五分之一的病例中被认为是促成原因。复发时治疗患者的局部控制率与初始放疗患者相当。可能可以对有利的患者(年龄≤50岁,肿瘤完全切除)术后安全观察,复发时再进行放疗。